<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116359</article-id><article-id pub-id-type="publisher-id">ACM-42863</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_70999383.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肝移植术后急性肾损伤的危险因素探究及列线图模型构建
  Acute Kidney Injury after Liver Transplantation: Risk Factors and Nomogram Model
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>美静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>健</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>雪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>建勋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>鑫</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>翠萍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院麻醉科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院消化内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2499</fpage><lpage>2506</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨肝移植(LT)术后急性肾损伤(AKI)的危险因素，构建列线图预测模型。方法：回顾性研究2017年1月至2019年8月在青岛大学附属医院接受LT手术244例患者临床资料。Logistic回归分析筛选术后AKI的危险因素，并以此构建列线图预测模型。结果：根据是否发生LT术后AKI将244例患者分为AKI组(n = 163)和非AKI组(n = 81)。与非AKI组相比，AKI组患者女性患者所占比例较高，BMI、MELD评分较高，术中失血量、术中输注红细胞较多，术前血肌酐(SCr)较低(P &lt; 0.05)。多因素Logistic回归分析显示性别、BMI、MELD评分、术前肾小球滤过率、术前血肌酐、术中输注红细胞、无肝期时间是LT术后AKI的独立危险因素。Hosmer-Lemeshow检验显示预测模型拟合优度较高(X
  <sup>2</sup> = 3.62, P = 0.89)。受试者特征曲线分析显示预测模型曲线下面积为0.77 (95% CI: 0.71~0.83)。结论：基于围术期危险因素构建的LT术后AKI发生风险的列线图预测模型校准度和区分能力较好，便于临床医师进行危险分层和早期识别，进而采取有效干预措施改善预后。
   Objective: To explore the risk factors of acute kidney injury (AKI) after liver transplantation (LT) and establish a nomogram to predict the incidence of AKI after LT individually. Methods: The clinical data of 244 patients who underwent LT in the Affiliated Hospital of Qingdao University between January 2017 and August 2019 were retrospectively analyzed. Logistic regression methods were used to screen the risk factors of AKI after LT, and then to establish the nomogram to individually predict the incidence of AKI after LT. Results: According to the episode of AKI (yes/no), patients were divided into the AKI group (n = 163) and the non-AKI group (n = 81). Compared with patients without AKI, patients with AKI had higher proportion of female gender, higher body mass index, higher MELD score, higher intraoperative blood loss, higher intraoperative RBC transfusion and lower preoperative serum creatinine (P &lt; 0.05). Multivariate Logistic regression analysis showed that gender, body mass index, MELD score, preoperative glomerular filtration rate, preoperative serum creatinine, intraoperative RBC transfusion, anhepatic time were independent risk factors for AKI after LT. Hosmer-Lemeshow test showed that the goodness of fit of the prediction model was good (X
  <sup>2</sup> = 3.62, P = 0.89). Receiver operating characteristic curve showed that the area under the curve predicted by prediction model for AKI after LT was 0.77 (95% CI: 0.71~0.83). Conclusion: Based on the perioperative risk factors for AKI after LT, a nomogram model for predicting the incidence of AKI after LT is established, which has a good calibration and discrimination, and can help clinicians with risk stratification and early recognition, thus enabling effective intervention to improve outcomes.
 
</p></abstract><kwd-group><kwd>肝移植，急性肾损伤，危险因素，回归分析，列线图, Liver Transplantation</kwd><kwd> Acute Kidney Injury</kwd><kwd> Risk Factor</kwd><kwd> Regression Analysis</kwd><kwd> Nomogram</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨肝移植(LT)术后急性肾损伤(AKI)的危险因素，构建列线图预测模型。方法：回顾性研究2017年1月至2019年8月在青岛大学附属医院接受LT手术244例患者临床资料。Logistic回归分析筛选术后AKI的危险因素，并以此构建列线图预测模型。结果：根据是否发生LT术后AKI将244例患者分为AKI组(n = 163)和非AKI组(n = 81)。与非AKI组相比，AKI组患者女性患者所占比例较高，BMI、MELD评分较高，术中失血量、术中输注红细胞较多，术前血肌酐(SCr)较低(P &lt; 0.05)。多因素Logistic回归分析显示性别、BMI、MELD评分、术前肾小球滤过率、术前血肌酐、术中输注红细胞、无肝期时间是LT术后AKI的独立危险因素。Hosmer-Lemeshow检验显示预测模型拟合优度较高(X<sup>2</sup> = 3.62, P = 0.89)。受试者特征曲线分析显示预测模型曲线下面积为0.77 (95% CI: 0.71~0.83)。结论：基于围术期危险因素构建的LT术后AKI发生风险的列线图预测模型校准度和区分能力较好，便于临床医师进行危险分层和早期识别，进而采取有效干预措施改善预后。</p></sec><sec id="s2"><title>关键词</title><p>肝移植，急性肾损伤，危险因素，回归分析，列线图</p></sec><sec id="s3"><title>Acute Kidney Injury after Liver Transplantation: Risk Factors and Nomogram Model<sup> </sup></title><p>Meijing Zhu<sup>1</sup>, Jian Zhou<sup>2</sup>, Xue Wang<sup>1</sup>, Jianxun Liu<sup>1</sup>, Xin Yang<sup>1</sup>, Cuiping Zhang<sup>1</sup></p><p><sup>1</sup>Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/1-1572187x4_hanspub.png" /></p><p>Received: May 1<sup>st</sup>, 2021; accepted: May 13<sup>th</sup>, 2021; published: Jun. 1<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/1-1572187x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the risk factors of acute kidney injury (AKI) after liver transplantation (LT) and establish a nomogram to predict the incidence of AKI after LT individually. Methods: The clinical data of 244 patients who underwent LT in the Affiliated Hospital of Qingdao University between January 2017 and August 2019 were retrospectively analyzed. Logistic regression methods were used to screen the risk factors of AKI after LT, and then to establish the nomogram to individually predict the incidence of AKI after LT. Results: According to the episode of AKI (yes/no), patients were divided into the AKI group (n = 163) and the non-AKI group (n = 81). Compared with patients without AKI, patients with AKI had higher proportion of female gender, higher body mass index, higher MELD score, higher intraoperative blood loss, higher intraoperative RBC transfusion and lower preoperative serum creatinine (P &lt; 0.05). Multivariate Logistic regression analysis showed that gender, body mass index, MELD score, preoperative glomerular filtration rate, preoperative serum creatinine, intraoperative RBC transfusion, anhepatic time were independent risk factors for AKI after LT. Hosmer-Lemeshow test showed that the goodness of fit of the prediction model was good (X<sup>2</sup> = 3.62, P = 0.89). Receiver operating characteristic curve showed that the area under the curve predicted by prediction model for AKI after LT was 0.77 (95% CI: 0.71~0.83). Conclusion: Based on the perioperative risk factors for AKI after LT, a nomogram model for predicting the incidence of AKI after LT is established, which has a good calibration and discrimination, and can help clinicians with risk stratification and early recognition, thus enabling effective intervention to improve outcomes.</p><p>Keywords:Liver Transplantation, Acute Kidney Injury, Risk Factor, Regression Analysis, Nomogram</p><disp-formula id="hanspub.42863-formula2"><graphic xlink:href="//html.hanspub.org/file/1-1572187x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1572187x7_hanspub.png" /> <img src="//html.hanspub.org/file/1-1572187x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>急性肾损伤(AKI)是肝移植(LT)术后常见并发症，发生率约为40.8% [<xref ref-type="bibr" rid="hanspub.42863-ref1">1</xref>]。AKI不仅引起容量超负荷、代谢性酸中毒、电解质紊乱等病理生理改变 [<xref ref-type="bibr" rid="hanspub.42863-ref2">2</xref>]，而且与术后感染、移植物失功、慢性肾脏病、住院死亡率、医疗费用增加等密切相关 [<xref ref-type="bibr" rid="hanspub.42863-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.42863-ref3">3</xref>]。探究LT术后AKI相关危险因素，建立列线图风险预测模型对于指导临床工作具有重要意义。已有研究发现性别、超重、终末期肝病模型(MELD)评分、术中输注红细胞、他克莫司血药浓度等可能是LT术后AKI的危险因素 [<xref ref-type="bibr" rid="hanspub.42863-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.42863-ref2">2</xref>]，但这些因素尚不明确且存在种族差异。目前关于LT术后AKI的列线图预测模型鲜见报道。故本研究拟通过回顾性分析244例LT患者的临床资料，探究LT术后AKI的危险因素，建立列线图预测模型，从而达到早期个体化评估LT术后AKI发生风险的目的。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>采用单中心回顾性队列研究方法。收集2017年~2019年共341例在我院接受LT患者的临床资料。采用医学数据智能平台结合电子病历提取数据。手术方式采用经典原位LT或改良背驮式原位LT，手术均由同一经验丰富的医疗团队完成。受者术后采用他克莫司 + 吗替麦考酚酯 + 激素三联免疫抑制方案。本研究通过我院医学伦理委员会审批(伦理审批号：QYFY WZLL 25725)，符合《世界医学协会赫尔辛基宣言》人体对象医学研究的道德原则。排除标准：1) 患者年龄 &lt; 18岁(12人)；2) 行肝肾联合移植(11人)；术前因肾功能障碍需要行肾脏替代治疗(3人)；3) 既往肾移植手术史(4人)；4) 再次LT (7人)；5) 重要数据缺失(60人)。</p></sec><sec id="s6_2"><title>2.2. 临床资料</title><p>1) 术前资料：患者年龄、性别、体重质量指数(BMI)、吸烟史、饮酒史、原发病(肝恶性肿瘤合病毒性肝炎、肝恶性肿瘤、病毒性肝炎、酒精性肝硬化、其他(自身免疫性肝炎、胆源性肝硬化、布加综合征、威尔逊病、药物性肝炎、隐源性肝炎)、合并症(高血压、糖尿病、高脂血症、慢性肾脏病、乙型病毒性肝炎、丙型病毒性肝炎、肝性脑病、腹水)、肾小球滤过率、MELD评分、Child-Pugh评分、检验指标(肌酐、白蛋白、总胆红素、钠、乳酸、葡萄糖)。</p><p>2) 术中资料：手术时间、冷缺血时间、无肝期时间、术中出血量、术中总输液量、术中输注红细胞悬液量、术中血压最低值、术中是否使用血管活性药物。</p><p>3) 术后资料：血清肌酐值、他克莫司血药浓度、术后24小时血清谷草转氨酶峰值(作为再灌注损伤标志物) [<xref ref-type="bibr" rid="hanspub.42863-ref2">2</xref>]、是否接受肾脏替代治疗、术后住院日、是否住院期间死亡。</p></sec><sec id="s6_3"><title>2.3. AKI的诊断</title><p>依据改善全球肾脏病预后组织(KDIGO)标准 [<xref ref-type="bibr" rid="hanspub.42863-ref4">4</xref>]，AKI定义为48 h内SCr升高 ≥ 26.5 &#181;mol/L或者7 d内SCr升高超过基础值的1.5倍及以上。并对诊断AKI患者进行分期：1期为SCr于48 h内升高 ≥ 26.5 &#181;mol/L或SCr升高达基础值的1.5~1.9倍；2期为SCr升高达基础值的2~2.9倍；3期为SCr升高超过基础值的3倍或SCr ≥ 353.6 &#181;mol/L或需要肾脏替代治疗。</p></sec><sec id="s6_4"><title>2.4. 统计学分析</title><p>采用SPSS 23.0统计学软件进行分析。正态分布的计量资料以均数&#177;标准差( x &#175; &#177; s )表示，组间比较采用成组t检验；偏态分布的计量资料以中位数(四分位数) [M(Q)]表示，组间比较采用秩和检验；计数资料以频数(百分数)表示，组间比较采用 X 2 检验或Fisher确切概率。采用多因素logistic回归分析，以基于Wald统计量的向后逐步回归法筛选LT术后AKI的危险因素，构建列线图预测模型。</p><p>采用R3.6.3软件中rms程序包绘制列线图。采用Bootstrap法重复抽样1000次对列线图模型进行内部验证。采用Hosmer-Lemeshow拟合优度检验评价预测模型的校准度。采用受试者特征曲线下面积评价预测模型区分能力。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. AKI组和非AKI组患者临床资料的比较</title><p>本研究共纳入患者244例，术后发生AKI的患者163例(66.8%)。其中，12例(4.9%)需在ICU启动肾脏替代治疗。其中，1期为76例，2期为52例，3期为35例，分别占总病例数的46.6%，31.9%，21.5%。与非AKI组相比，AKI组患者女性患者所占比例较高，BMI、MELD评分较高，术中失血量、术中输注红细胞较多，术前血肌酐较低，差异有统计学意义(P &lt; 0.05)。具体内容见表1~3。</p></sec><sec id="s7_2"><title>3.2. AKI的危险因素分析及预测模型构建</title><p>将AKI组和非AKI组组间比较有统计学差异的因素视为LT术后AKI可能的危险因素(为避免漏掉一些重要因素，此处认为P &lt; 0.15差异即有统计学意义)并纳入多因素Logistic回归分析。这些因素有性别、BMI、高脂血症、乙型病毒性肝炎、MELD评分、术前肾小球滤过率、术前血肌酐、术前血乳酸、术中失血量、术中输注红细胞、无肝期时间。使用Box-Tidwell方法检验连续自变量与因变量logit转换值间是否为线性。线性检验模型共纳入19项，Bonferroni校正后显著性水平为0.0026。线性检验结果得到所有连续自变量与因变量logit转换值间存在线性关系。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of preoperative clinical data between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >总样本量 N = 244</th><th align="center" valign="middle" >AKI组 N = 163(66.8%)</th><th align="center" valign="middle" >非AKI组 N = 81 (33.2%)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >患者基线资料</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄(年)</td><td align="center" valign="middle" >54.1 (9.6)</td><td align="center" valign="middle" >54.6 (9.5)</td><td align="center" valign="middle" >53.2 (9.7)</td><td align="center" valign="middle" >0.23</td></tr><tr><td align="center" valign="middle" >性别，女[例(%)]</td><td align="center" valign="middle" >39 (16.0)</td><td align="center" valign="middle" >33 (20.2)</td><td align="center" valign="middle" >6 (7.4)</td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" >BMI [M(Q), kg/m<sup>2</sup>]</td><td align="center" valign="middle" >24.4 (21.6, 26.6)</td><td align="center" valign="middle" >24.7 (22.5, 27.1)</td><td align="center" valign="middle" >23.0 (20.8, 25.6)</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >个人史</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >吸烟史[例(%)]</td><td align="center" valign="middle" >88 (36.1)</td><td align="center" valign="middle" >59 (36.2)</td><td align="center" valign="middle" >29 (35.8)</td><td align="center" valign="middle" >0.95</td></tr><tr><td align="center" valign="middle" >饮酒史[例(%)]</td><td align="center" valign="middle" >94 (38.5)</td><td align="center" valign="middle" >59 (36.2)</td><td align="center" valign="middle" >35 (43.2)</td><td align="center" valign="middle" >0.29</td></tr><tr><td align="center" valign="middle" >合并症</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高血压[例(%)]</td><td align="center" valign="middle" >69 (28.3)</td><td align="center" valign="middle" >44 (27.0)</td><td align="center" valign="middle" >25 (30.9)</td><td align="center" valign="middle" >0.53</td></tr><tr><td align="center" valign="middle" >糖尿病[例(%)]</td><td align="center" valign="middle" >86 (35.2)</td><td align="center" valign="middle" >58 (35.6)</td><td align="center" valign="middle" >28 (34.6)</td><td align="center" valign="middle" >0.88</td></tr><tr><td align="center" valign="middle" >高脂血症[例(%)]</td><td align="center" valign="middle" >114 (46.7)</td><td align="center" valign="middle" >69 (42.3)</td><td align="center" valign="middle" >45 (55.6)</td><td align="center" valign="middle" >0.05</td></tr><tr><td align="center" valign="middle" >慢性肾脏病[例(%)]</td><td align="center" valign="middle" >30 (12.3)</td><td align="center" valign="middle" >20 (12.3)</td><td align="center" valign="middle" >10 (12.3)</td><td align="center" valign="middle" >0.99</td></tr><tr><td align="center" valign="middle" >乙型病毒性肝炎[例(%)]</td><td align="center" valign="middle" >125 (51.2)</td><td align="center" valign="middle" >78 (47.9)</td><td align="center" valign="middle" >47 (58.0)</td><td align="center" valign="middle" >0.13</td></tr><tr><td align="center" valign="middle" >丙型病毒性肝炎[例(%)]</td><td align="center" valign="middle" >10 (4.1)</td><td align="center" valign="middle" >6 (3.7)</td><td align="center" valign="middle" >4 (4.9)</td><td align="center" valign="middle" >0.64</td></tr><tr><td align="center" valign="middle" >肝性脑病[例(%)]</td><td align="center" valign="middle" >17 (7.0)</td><td align="center" valign="middle" >11 (6.7)</td><td align="center" valign="middle" >6 (7.4)</td><td align="center" valign="middle" >0.85</td></tr><tr><td align="center" valign="middle" >腹水[例(%)]</td><td align="center" valign="middle" >55 (22.5)</td><td align="center" valign="middle" >37 (22.7)</td><td align="center" valign="middle" >18 (22.2)</td><td align="center" valign="middle" >0.93</td></tr><tr><td align="center" valign="middle" >原发病</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.36</td></tr><tr><td align="center" valign="middle" >肝恶性肿瘤合并病毒性肝炎[例(%)]</td><td align="center" valign="middle" >103 (42.2)</td><td align="center" valign="middle" >65 (39.9)</td><td align="center" valign="middle" >38 (46.9)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肝恶性肿瘤[例(%)]</td><td align="center" valign="middle" >48 (19.7)</td><td align="center" valign="middle" >36 (22.1)</td><td align="center" valign="middle" >12 (14.8)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病毒性肝炎[例(%)]</td><td align="center" valign="middle" >51 (20.9)</td><td align="center" valign="middle" >32 (19.6)</td><td align="center" valign="middle" >19 (23.5)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >酒精性肝病[例(%)]</td><td align="center" valign="middle" >18 (7.3)</td><td align="center" valign="middle" >11 (6.7)</td><td align="center" valign="middle" >7 (8.6)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >其他[例(%)]</td><td align="center" valign="middle" >24 (9.8)</td><td align="center" valign="middle" >19 (11.7)</td><td align="center" valign="middle" >5 (6.2)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肾小球滤过率[M(Q), ml/min&#183;1.73 m<sup>2</sup>]</td><td align="center" valign="middle" >141.5 (105.0, 181.0)</td><td align="center" valign="middle" >145.0 (108.4, 186.3)</td><td align="center" valign="middle" >129.1 (103.5, 163.3)</td><td align="center" valign="middle" >0.14</td></tr><tr><td align="center" valign="middle" >CTP评分</td><td align="center" valign="middle" >8 (7, 9)</td><td align="center" valign="middle" >8 (7, 9)</td><td align="center" valign="middle" >8 (7, 9)</td><td align="center" valign="middle" >0.27</td></tr><tr><td align="center" valign="middle" >MELD评分</td><td align="center" valign="middle" >9 (5, 15)</td><td align="center" valign="middle" >10 (6, 16)</td><td align="center" valign="middle" >7 (2, 15)</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >检验结果</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肌酐[M(Q), mg/dL]</td><td align="center" valign="middle" >67 (54, 82)</td><td align="center" valign="middle" >65 (50, 78)</td><td align="center" valign="middle" >71 (64, 87)</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >钠[M(Q), mEq/L]</td><td align="center" valign="middle" >140 (138, 142)</td><td align="center" valign="middle" >140 (138, 142)</td><td align="center" valign="middle" >140 (137, 142)</td><td align="center" valign="middle" >0.86</td></tr><tr><td align="center" valign="middle" >白蛋白[M(Q), g/dL]</td><td align="center" valign="middle" >35.1 (30.7, 39.9)</td><td align="center" valign="middle" >35.0 (30.6, 39.7)</td><td align="center" valign="middle" >35.2 (30.9, 40.4)</td><td align="center" valign="middle" >0.58</td></tr><tr><td align="center" valign="middle" >总胆红素[M(Q), umol/L]</td><td align="center" valign="middle" >46.9 (24.7, 117.2)</td><td align="center" valign="middle" >49.1 (26.6, 129.3)</td><td align="center" valign="middle" >43.4 (20.9, 108.0)</td><td align="center" valign="middle" >0.57</td></tr><tr><td align="center" valign="middle" >血糖[M(Q), mg/dL]</td><td align="center" valign="middle" >5.1 (4.5, 6.4)</td><td align="center" valign="middle" >5.0 (4.4, 6.4)</td><td align="center" valign="middle" >5.2 (4.6, 6.2)</td><td align="center" valign="middle" >0.28</td></tr><tr><td align="center" valign="middle" >乳酸[M(Q), mmol/L]</td><td align="center" valign="middle" >1.3 (1.0, 1.6)</td><td align="center" valign="middle" >1.2 (1.0, 1.6)</td><td align="center" valign="middle" >1.3 (1.1, 1.8)</td><td align="center" valign="middle" >0.09</td></tr></tbody></table></table-wrap><p>表1. 两组患者术前临床资料比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of intraoperative clinical data between two groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >总样本量 N = 244</th><th align="center" valign="middle" >AKI组 N = 163 (66.8%)</th><th align="center" valign="middle" >非AKI组 N = 81 (33.2%)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >术中失血量[M(Q), L]</td><td align="center" valign="middle" >1.6 (1.0, 2.6)</td><td align="center" valign="middle" >2.0 (1.0, 2.8)</td><td align="center" valign="middle" >1.5 (1.0, 2.0)</td><td align="center" valign="middle" >0.04</td></tr><tr><td align="center" valign="middle" >术中输注红细胞[M(Q), U]</td><td align="center" valign="middle" >10.0 (6.0, 15.0)</td><td align="center" valign="middle" >12.0 (6.0, 17.5)</td><td align="center" valign="middle" >8.5 (4.0, 12.0)</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >术中平均动脉压最低值[M(Q), mmHg]</td><td align="center" valign="middle" >65 (62, 69)</td><td align="center" valign="middle" >65 (62, 69)</td><td align="center" valign="middle" >65 (63, 70)</td><td align="center" valign="middle" >0.92</td></tr><tr><td align="center" valign="middle" >术中应用升压药，是[例(%)]</td><td align="center" valign="middle" >87 (35.6)</td><td align="center" valign="middle" >56 (34.4)</td><td align="center" valign="middle" >31 (38.3)</td><td align="center" valign="middle" >0.82</td></tr><tr><td align="center" valign="middle" >手术时间[M(Q), min]</td><td align="center" valign="middle" >530 (470, 570)</td><td align="center" valign="middle" >531 (465, 575)</td><td align="center" valign="middle" >530 (470, 570)</td><td align="center" valign="middle" >0.81</td></tr><tr><td align="center" valign="middle" >冷缺血时间[M(Q), min]</td><td align="center" valign="middle" >382 (325, 382)</td><td align="center" valign="middle" >382 (326, 384)</td><td align="center" valign="middle" >383 (325, 387)</td><td align="center" valign="middle" >0.63</td></tr><tr><td align="center" valign="middle" >无肝期时间[M(Q), min]</td><td align="center" valign="middle" >60 (53, 60)</td><td align="center" valign="middle" >60 (52, 60)</td><td align="center" valign="middle" >60 (56, 64)</td><td align="center" valign="middle" >0.13</td></tr></tbody></table></table-wrap><p>表2. 两组患者术中临床资料比较</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of postoperative clinical data between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >总样本量 N = 244</th><th align="center" valign="middle" >AKI组 N = 163 (66.8%)</th><th align="center" valign="middle" >非AKI组 N = 81(33.2%)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >术后AST峰值[M(Q), U/L]</td><td align="center" valign="middle" >510.5 (75.0, 792.8)</td><td align="center" valign="middle" >526.0 (72.0, 796.0)</td><td align="center" valign="middle" >289.5 (80.5, 743.5)</td><td align="center" valign="middle" >0.80</td></tr><tr><td align="center" valign="middle" >他克莫司血药浓度[M(Q), ng/mL]</td><td align="center" valign="middle" >8.8 (6.4, 11.8)</td><td align="center" valign="middle" >9.0 (6.6, 11.5)</td><td align="center" valign="middle" >8.2 (6.3, 12.2)</td><td align="center" valign="middle" >0.66</td></tr><tr><td align="center" valign="middle" >术后接受肾脏替代治疗[例(%)]</td><td align="center" valign="middle" >12 (7.4)</td><td align="center" valign="middle" >12 (7.4)</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" >术后住院日[M(Q), d]</td><td align="center" valign="middle" >27 (21, 29)</td><td align="center" valign="middle" >27 (21, 30)</td><td align="center" valign="middle" >25 (20, 28)</td><td align="center" valign="middle" >0.33</td></tr><tr><td align="center" valign="middle" >住院期间死亡，是[例(%)]</td><td align="center" valign="middle" >7 (2.9)</td><td align="center" valign="middle" >5 (3.1)</td><td align="center" valign="middle" >2 (2.5)</td><td align="center" valign="middle" >0.99</td></tr></tbody></table></table-wrap><p>表3. 两组患者术后临床资料比较</p><p>最终，得到的Logistic模型具有统计学意义，X<sup>2</sup> = 56.18，P &lt; 0.0001。具体概率回归方程为：P = e<sup>x</sup>/(1 + e<sup>x</sup>), x = −2.680 + 1.549 &#215; 性别(女) + 0.190 &#215; BMI (kg/m<sup>2</sup>) − 0.590 &#215; 乙型病毒性肝炎 + 0.042 &#215; MELD评分 + 0.006 &#215; 术前肾小球滤过率(ml/min&#183;1.73m<sup>2</sup>) − 0.018 &#215; 术前血肌酐(mg/dL) + 0.040 &#215; 术中输入红细胞(U) − 0.025 &#215; 无肝期时间(min)。模型纳入的11个变量中，性别、BMI、乙型病毒性肝炎、MELD评分、术前肾小球滤过率、术前血肌酐、术中输入红细胞和无肝期时间是LT术后AKI的独立危险因素。具体内容见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Binary logistic regression analysi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >回归系数β</th><th align="center" valign="middle" >标准误</th><th align="center" valign="middle" >P值</th><th align="center" valign="middle" >OR (95% CI)</th></tr></thead><tr><td align="center" valign="middle" >性别(女)</td><td align="center" valign="middle" >1.594</td><td align="center" valign="middle" >0.552</td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" >4.707 (1.595~13.888)</td></tr><tr><td align="center" valign="middle" >体重质量指数(kg/m<sup>2</sup>)</td><td align="center" valign="middle" >0.190</td><td align="center" valign="middle" >0.049</td><td align="center" valign="middle" >&lt;0.0001</td><td align="center" valign="middle" >1.209 (1.098~1.332)</td></tr><tr><td align="center" valign="middle" >乙型病毒性肝炎</td><td align="center" valign="middle" >−0.590</td><td align="center" valign="middle" >0.317</td><td align="center" valign="middle" >0.063</td><td align="center" valign="middle" >0.554 (0.298~1.031)</td></tr><tr><td align="center" valign="middle" >MELD评分</td><td align="center" valign="middle" >0.042</td><td align="center" valign="middle" >0.020</td><td align="center" valign="middle" >0.031</td><td align="center" valign="middle" >1.043 (1.004~1.084)</td></tr><tr><td align="center" valign="middle" >术前肾小球滤过率(ml/min&#183;1.73m<sup>2</sup>)</td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.012</td><td align="center" valign="middle" >1.006 (1.001~1.011)</td></tr><tr><td align="center" valign="middle" >术前血肌酐(umol/L)</td><td align="center" valign="middle" >−0.018</td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.982 (0.971~0.994)</td></tr><tr><td align="center" valign="middle" >术中输入红细胞(U)</td><td align="center" valign="middle" >0.040</td><td align="center" valign="middle" >0.020</td><td align="center" valign="middle" >0.043</td><td align="center" valign="middle" >1.040 (1.001~1.081)</td></tr><tr><td align="center" valign="middle" >无肝期时间(min)</td><td align="center" valign="middle" >−0.025</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" >0.009</td><td align="center" valign="middle" >0.975 (0.957~0.994)</td></tr><tr><td align="center" valign="middle" >常量</td><td align="center" valign="middle" >−2.680</td><td align="center" valign="middle" >1.412</td><td align="center" valign="middle" >0.058</td><td align="center" valign="middle" >0.069 (−)</td></tr></tbody></table></table-wrap><p>表4. 二元logistic回归分析</p></sec><sec id="s7_3"><title>3.3. 预测模型的评价及列线图的临床应用</title><p>该预测模型能够正确分类75.3%的研究对象。模型的敏感度为91.4%，特异度为42.5%，阳性预测值为76.4%，阴性预测值为70.8%。采用Hosmer-Lemeshow拟合优度检验评价该模型校准度，结果显示X<sup>2</sup> = 3.62，P = 0.89，认为当前数据中的信息已经被充分提取，预测模型的校准度较好。采用受试者特征曲线下面积评价预测模型区分能力，结果显示AUC (95% CI) = 0.77 (0.71~0.83)，认为该模型区分能力较好。</p><p>应用R软件绘制列线图从而将预测模型可视化便于临床应用，具体内容见图1。根据每个危险因素实际值对应的变量轴上相应点，以该点做变量轴的垂直线对应至上方评分尺，得到该危险因素的得分。通过对各危险因素得分求和得总分，总分对应在AKI风险轴的点，即为相对应的LT术后AKI的风险概率。</p><p>图1. 预测LT术后AKI的列线图</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>AKI是一种复杂的综合征，表现为从轻度肌酐升高到无尿期肾衰竭等一系列肾功能急剧恶化 [<xref ref-type="bibr" rid="hanspub.42863-ref5">5</xref>]。AKI是LT术后常见并发症，研究报道其发生率在5%~94%之间 [<xref ref-type="bibr" rid="hanspub.42863-ref1">1</xref>]，不同研究间AKI发生率的差异可能是由于AKI缺乏统一的诊断标准。LT术后AKI的患者中，大约有8%~17%的患者需接受肾脏替代治疗 [<xref ref-type="bibr" rid="hanspub.42863-ref6">6</xref>]。大量研究证据表明LT术后AKI与受体及移植物短期及长期不良预后有关，甚至危及受体生命。此外，有研究表明，即便轻微短暂的AKI也与术后心血管事件不良预后密切相关 [<xref ref-type="bibr" rid="hanspub.42863-ref7">7</xref>]。许多研究旨在探索LT术后AKI的药物或非药物干预措施，但目前仍缺乏有效防治手段。因此了解LT术后AKI相关危险因素、建立风险预测模型便于早期识别与危险分层，对于指导临床工作具有重要意义。</p><p>本研究发现，女性患者比男性患者患肝移植术后急性肾损伤的风险增加3.7倍。Hilmi等的研究同样显示女性患者为LT术后AKI的独立危险因素 [<xref ref-type="bibr" rid="hanspub.42863-ref8">8</xref>]，与本研究结果一致。在本研究的风险预测模型中，BMI每增加一个单位，患LT术后AKI的风险增加20.9%。其原因可能是超重和肥胖导致肾小球滤过率增加、尿白蛋白丢失增加，以及局灶节段性肾小球硬化有关的肾功能恶化。这种肥胖相关的超微结构和功能改变统称为肥胖相关肾小球疾病 [<xref ref-type="bibr" rid="hanspub.42863-ref9">9</xref>]。此外，有学者认为肥胖是一种慢性低炎症状态，激活相关信号通路并产生脂类促炎分子，而脂类促炎分子可能在急性肾缺血/再灌注损伤的发病机制中起关键作用 [<xref ref-type="bibr" rid="hanspub.42863-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.42863-ref11">11</xref>]。本研究中，MELD评分越高，LT术后AKI发病风险越高。MELD评分能有效地评估终末期肝病患者病情的严重程度 [<xref ref-type="bibr" rid="hanspub.42863-ref12">12</xref>]，这反应出LT术前肝功能情况与术后AKI密切相关。有研究发现，MELD评分不仅可以预测LT术后存活率，也是术后肾功能不全需要肾脏替代治疗的独立危险因素 [<xref ref-type="bibr" rid="hanspub.42863-ref13">13</xref>]。本研究结果显示，术中输注红细胞是LT术后AKI的独立危险因素。一方面，术中输注大量红细胞可激活氧化应激、促进炎症反应，使肾脏氧输送调节受损，继而造成更严重的缺血–再灌注损伤 [<xref ref-type="bibr" rid="hanspub.42863-ref14">14</xref>]；另一方面，这也间接反映出术中血流动力学变化对肾脏血流灌注的重要影响。因此，维持术中血流动力学平稳可能有助于减少LT术后AKI的发生。</p><p>本研究中通过单因素分析、多因素分析确定LT术后AKI的危险因素。基于患者围术期临床资料构建风险预测模型，具有良好的区分度与校准度，利用R语言绘制预测LT术后AKI的列线图将风险预测模型可视化，根据列线图能快速计算出每位LT患者相对应的AKI发病风险。有助于临床医师直观地分析各个危险因素的不同风险比重及术后即刻个体化预测发病风险，从而进行危险分层和早期识别，并采取有效干预措施。</p><p>本研究具有一定的局限性。首先，本研究为单中心回顾性队列研究，所得的风险预测模型有待多中心、大样本的研究进一步证实；其次，本研究没有对供体相关因素进行分析，在下一步的研究中应进行补充。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，LT术后AKI的发病机制受多种因素影响。基于患者围术期临床资料绘制预测LT术后AKI的列线图有助于临床医师早期识别并采取有效干预措施。</p></sec><sec id="s10"><title>文章引用</title><p>朱美静,周 健,王 雪,刘建勋,杨 鑫,张翠萍. 肝移植术后急性肾损伤的危险因素探究及列线图模型构建Acute Kidney Injury after Liver Transplantation: Risk Factors and Nomogram Model[J]. 临床医学进展, 2021, 11(06): 2499-2506. https://doi.org/10.12677/ACM.2021.116359</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42863-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Thongprayoon, C., Kaewput, W., Thamcharoen, N., et al. (2019) Incidence and Impact of Acute Kidney Injury after Liver Transplantation: A Meta-Analysis. Journal of Clinical Medicine, 8, 372. &lt;br&gt;https://doi.org/10.3390/jcm8030372</mixed-citation></ref><ref id="hanspub.42863-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">de Haan, J.E., Hoorn, E.J. and de Geus, H.R.H. (2017) Acute Kidney Injury after Liver Transplantation: Recent Insights and Future Perspectives. Best Practice and Research. Clinical Gastroenterology, 31, 161-169.  
&lt;br&gt;https://doi.org/10.1016/j.bpg.2017.03.004</mixed-citation></ref><ref id="hanspub.42863-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Durand, F., Francoz, C., Asrani, S.K., et al. (2018) Acute Kidney Injury after Liver Transplantation. Transplantation, 102, 1636-1649. &lt;br&gt;https://doi.org/10.1097/TP.0000000000002305</mixed-citation></ref><ref id="hanspub.42863-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International, 2, 1-138.</mixed-citation></ref><ref id="hanspub.42863-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ronco, C., Bellomo, R. and Kellum, J.A. (2019) Acute Kidney Injury. Lancet, 394, 1949-1964.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(19)32563-2</mixed-citation></ref><ref id="hanspub.42863-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zongyi, Y., Baifeng, L., Funian, Z., et al. (2017) Risk Factors of Acute Kidney Injury after Orthotopic Liver Transplantation in China. Scientific Reports, 7, 41555. &lt;br&gt;https://doi.org/10.1038/srep41555</mixed-citation></ref><ref id="hanspub.42863-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">De Virgilio, C. and Kim, D.Y. (2016) Transient Acute Kidney Injury in the Postoperative Period: It Is Time to Pay Closer Attention. JAMA Surgery, 151, 450-451. &lt;br&gt;https://doi.org/10.1001/jamasurg.2015.4660</mixed-citation></ref><ref id="hanspub.42863-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hilmi, I.A., Damian, D., Al-Khafaji, A., et al. (2015) Acute Kidney Injury Following Orthotopic Liver Transplantation: Incidence, Risk Factors, and Effects on Patient and Graft Outcomes. British Journal of Anaesthesia, 114, 919-926.  
&lt;br&gt;https://doi.org/10.1093/bja/aeu556</mixed-citation></ref><ref id="hanspub.42863-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Suneja, M. and Kumar, A.B. (2014) Obesity and Perioperative Acute Kidney Injury: A Focused Review. Journal of Critical Care, 29, 694.e1-6. &lt;br&gt;https://doi.org/10.1016/j.jcrc.2014.02.021</mixed-citation></ref><ref id="hanspub.42863-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Oh, J. and Rabb, H. (2013) Adiponectin: An Enlarging Role in Acute Kidney Injury. Kidney International, 83, 546-548. &lt;br&gt;https://doi.org/10.1038/ki.2012.479</mixed-citation></ref><ref id="hanspub.42863-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Jin, X., Chen, J., Hu, Z., et al. (2013) Genetic Deficiency of Adiponectin Protects Against Acute Kidney Injury. Kidney International, 83, 604-614. &lt;br&gt;https://doi.org/10.1038/ki.2012.408</mixed-citation></ref><ref id="hanspub.42863-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Freeman, R.J. (2002) The New Liver Allocation System: Moving toward Evidence-Based Transplantation Policy. Liver Transplantation, 8, 851-858. &lt;br&gt;https://doi.org/10.1053/jlts.2002.35927</mixed-citation></ref><ref id="hanspub.42863-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Gomes, R.T., Ivana, S., Queiroz, S.F.M.D., et al. (2013) Role of MELD Score and Serum Creatinine as Prognostic Tools for the Development of Acute Kidney Injury after Liver Transplantation. Public Library of Science One, 8, e64089. &lt;br&gt;https://doi.org/10.1371/journal.pone.0064089</mixed-citation></ref><ref id="hanspub.42863-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Karkouti, K. (2012) Transfusion and Risk of Acute Kidney Injury in Cardiac Surgery. British Journal of Anaesthesia, 109, i29-i38. &lt;br&gt;https://doi.org/10.1093/bja/aes422</mixed-citation></ref></ref-list></back></article>